The next 4DX? More like Shockwave Medical

In an era where software moats erode overnight and AI compresses entire industries into a single API call, we are drawn to businesses fortified by things that cannot be copied quickly—twenty years of physics R&D, 91 hardware patents, MRI-vendor ecosystem lock-in, and layers of FDA clearance that take a decade to replicate. Imricor (ASX: IMR) sits behind all four.

The Investment Case

Imricor belongs to a rare class of medtech company we call category creators — businesses that invent an entirely new treatment modality, hold a monopoly position from day one, and face no direct competition. It is the only company on earth with a commercially viable MRI-compatible cardiac ablation system, backed by 91 patents. We have seen this playbook before. Shockwave Medical created intravascular lithotripsy and traded at US$428M at its 2019 IPO — almost identical to Imricor's US$410M market cap today — before delivering a 31x return via a US$13.1 billion J&J acquisition five years later. 

4DMedical (ASX: 4DX), another ASX-listed category creator with zero competitors and deep IP, is ~12 months ahead of Imricor on FDA clearance and already trades at A$2.14 billion — more than three times Imricor's valuation. The structural parallels across all three are striking: monopoly position, zero competition, patent fortress, billion-dollar TAM, and marquee strategic partners. We believe the current price dramatically undervalues the optionality.

“This ground-breaking technology will fundamentally change the way we think about the treatment of cardiac arrhythmias”

Dr. Marco Götte — Imaging Cardiologist, Amsterdam UMC

What Imricor Does

Over a million cardiac ablation procedures are performed globally every year. Every one is done under X-ray. The electrophysiologist can see bones and metal but cannot see the heart tissue, cannot assess lesion quality, and cannot confirm whether the procedure worked. This is the fundamental limitation of modern electrophysiology—and the reason procedure times for complex arrhythmias like ventricular tachycardia can exceed eight hours with success rates as low as 40%.

Imricor moves the entire procedure into the MRI scanner. Its platform—the Vision-MR Ablation Catheter, NorthStar 3D Mapping System, and Advantage-MR Recorder—gives the operator real-time 3D visualisation of anatomy, catheter position, and lesion formation as it happens. The foundational IP originated at Johns Hopkins University and Philips, with twenty years of R&D behind it. Both Siemens Healthineers (5.9% equity stake) and Philips (formal sales agreement) have built their iCMR lab designs around Imricor’s products.

Market Size

The global electrophysiology devices market is growing from ~US$10 billion today to ~US$33 billion by 2032 at 15% CAGR (S&S Insider, per Imricor investor presentation, February 2026). There are 7,500 EP labs globally, with 2,500 in the US alone.

Imricor’s own unit economics show each top-50 US hospital (operating 3+ EP labs) represents US$9.43 million per year in consumable revenue across atrial flutter ($1.7M), ventricular tachycardia ($1.1M), and atrial fibrillation ($6.6M)—approximately $3 million per lab. At the same time, hospitals save US$4.62 million per year in device costs versus X-ray-guided procedures, before lab time savings exceeding $2,000/hour.

The bottom-up TAM is substantial: 7,500 labs at $3M+ per lab represents a potential addressable market exceeding US$22 billion in annual consumable revenue. Our base-case revenue forecast of US$270M by FY2029 requires just 190 labs—roughly 2.5% of the global base.

Where They Are and What’s Next

Imricor was founded in 2006 by Steve Wedan, a former GE Medical Systems MRI engineer. The company spent a decade developing MRI-safe catheter technology, secured its first CE Mark in 2020 following a study at the Leipzig Heart Centre that delivered 100% chronic effectiveness, and listed on the ASX in 2019. It has since built out its full product ecosystem—second-generation ablation catheter, NorthStar mapping, Advantage-MR recorder—secured CE Mark under the new EU MDR framework, and commenced two concurrent FDA clinical trials.

Near-Term Catalysts

• VISABL-AFL FDA submission and approval — PMA submission targeting Q3 2026. Two of three modules already filed. FDA clearance of the ablation catheter is the single highest-impact event—it unlocks the US market.

• Official commencement of US commercial sales — upon catheter clearance, Imricor begins selling its full product suite (catheter + NorthStar + recorder) into 2,500 US EP labs at $22,653/procedure reimbursement. The US sales and marketing team is already in place and preparing for launch.

• NorthStar US launch — FDA-cleared, inbound demand from paediatric hospitals. First revenue-generating US product ahead of catheter clearance.

• European commercial ramp — 40 hospital prospects in pipeline, targeting 10–15 active sites by end 2026.

• VT indication expansion — the indication where MRI guidance is most differentiated. Conventional VT: 8+ hours, 40% success. MRI-guided: real-time scar visualisation.

Category-Creator Comparables: 4DMedical & Shockwave 

Imricor belongs to a rare class of ASX-listed medtech: category creators with monopoly positions, deep patent portfolios, and massive addressable markets. Two companies—one ~12 months ahead on FDA clearance, one that completed the full journey to acquisition—provide the roadmap.

All three companies share the same structural DNA—category creation, monopoly position, zero competition, deep IP. 4DMedical is ~12 months ahead on FDA clearance and already scaling commercially at A$2.14B; it validates that the category-creator model works on the ASX in real time. Shockwave completed the full arc from US$428M IPO to US$13.1B takeout in five years. Imricor sits at the starting line at the same market cap Shockwave began from—but with significantly higher per-site economics ($9.43M/hospital vs ~$1.15M for 4DX) and the largest bottom-up TAM of the three at $22B+

Valuation: Shockwave’s Revenue Multiple Arc Applied to IMR 

Applying Shockwave’s actual EV/Revenue multiples at each equivalent commercial stage to Imricor’s base-case revenue, discounted to today at 12%:

The FY2027 row captures the FDA clearance catalyst: nominal A$14.68, or A$13.11 in today’s dollars. The acquisition scenario at FY2032 takes place at $67, discounted to $34. Even under a conservatively skewed probability distribution (60% bear / 35% base / 5% bull), the weighted present value is A$7.49—roughly 3.7x the current price.

Conclusion

Imricor is the only company with a commercially viable MRI-guided cardiac ablation system. It holds 91 patents. It has zero competitors. It operates in a market growing to US$33 billion. There are 7,500 addressable labs representing a $22 billion+ TAM. Siemens and Philips are building iCMR labs around its products. It has just performed the world’s first ischemic VT ablation under real-time MRI. Its market cap—US$410 million—matches Shockwave Medical’s at the same stage, before a 31x return. And the stock is A$2.00.